Evaxion To Present 1-Year Clinical Efficacy Data From Its Phase 2 Study On Lead Cancer Vaccine Candidate, EVX-01, At The ESMO Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech A/S (NASDAQ:EVAX) will present one-year clinical efficacy data from its Phase 2 study on its lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024. The vaccine is being tested in patients with advanced melanoma.
August 08, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech will present promising one-year clinical efficacy data for its lead cancer vaccine candidate, EVX-01, at the ESMO Congress 2024. This could positively impact the stock price as it demonstrates progress in their clinical trials.
The presentation of positive clinical efficacy data at a major oncology conference like ESMO is a significant milestone for Evaxion. It indicates progress in their clinical trials, which could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100